Levodopa-Induced Dyskinesia

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

HM
Hua MedicineChina - Shanghai
1 program
Tianqi Pingchan GranuleN/A1 trial
Active Trials
NCT04173845Unknown150Est. Dec 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Hua MedicineTianqi Pingchan Granule

Clinical Trials (1)

Total enrollment: 150 patients across 1 trials

NCT04173845Hua MedicineTianqi Pingchan Granule

Double Randomized and Placebo Controlled Trail of Tianqi Pingchan Granule to Prevent Levodopa-Induced Dyskinesia

Start: Sep 2019Est. completion: Dec 2021150 patients
N/AUnknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space